6 Einträge gefunden

1. Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials

   1. Bieber, T
   2. Thyssen, J P
   3. Reich, K
   4. Simpson, E L
   5. Katoh, N
   6. Torrelo, A
   7. De Bruin-Weller, M

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
2. Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies

   1. Kimball, A B
   2. Papp, K A
   3. Reich, K
   4. Gooderham, M
   5. Li, Q
   6. Cichanowitz, N
   7. La Rosa, C

   2020 - Forschungsinformationssystem des UKE
3. An indirect comparison of long-term efficacy of every-2-week dosing vs. recommended dosing of ixekizumab in patients who had static Physician's Global Assessment > 1 at week 12

   1. Papp, K
   2. Maari, C
   3. Cauthen, A
   4. Gooderham, M
   5. Spelman, L
   6. Yamanaka, K
   7. Polzer, P

   2020 - Forschungsinformationssystem des UKE
4. Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: a pooled analysis of two randomized controlled trials

   1. Blauvelt, A
   2. Sofen, H
   3. Papp, K
   4. Gooderham, M
   5. Tyring, S
   6. Zhao, Y
   7. Lowry, S

   2019 - Forschungsinformationssystem des UKE
5. Rapid Improvements in Health-related Quality of Life and Itch with Ixekizumab Treatment in Randomized Phase 3 Trials: Results from UNCOVER-2 and UNCOVER-3

   1. Leonardi, Craig L
   2. Blauvelt, Andrew
   3. Sofen, H L
   4. Gooderham, M
   5. Augustin, M
   6. Burge, R
   7. Zhu, B

   2017 - Forschungsinformationssystem des UKE
6. Drug Survival of Biologic Therapy in a Large, Disease-based Registry of Patients with Psoriasis: Results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)

   1. Menter, A
   2. Papp, K A
   3. Gooderham, M
   4. Pariser, D M
   5. Augustin, M
   6. Kerdel, F A
   7. Fakharzadeh, S

   2016 - Forschungsinformationssystem des UKE